Details: pack, label wording, sources, registration
Silarsil 140 mg, Capsule
capsule, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Possible oral adjunct after veterinarian diagnosis and cause-directed treatment of a hepatobiliary disorder; not acute-toxin rescue, diagnosis or disease-modifying monotherapy
4.3/10
Weak evidence support
Details →
vetman assessment
Silarsil
×
140 mg, capsule, human medicine
Assessed clinical scope Dog · Possible oral adjunct after veterinarian diagnosis and cause-directed treatment of a hepatobiliary disorder; not acute-toxin rescue, diagnosis or disease-modifying monotherapy · By mouth
Care setting Veterinarian-directed outpatient adjunct with exact-product and dose-unit review, polypharmacy screening, objective disease monitoring and a defined reassessment/stop point.
vetman score
4.3/10
Weak evidence support
Evidence confidence: Low
Georgia: Yes, human · № რ-038256 · Verified on 22 Oct 2026
Off-label use
A traceable human native-silymarin capsule with plausible adjunctive rationale but no exact-product canine outcome or validated dose. Formulation-specific bioavailability and whole-capsule fit materially limit routine value.
Regulatory and scientific credibility 4.0/10
Exact 140 mg/30-capsule identity, World Medicine information and active Georgian and Azerbaijani human registrations are traceable, but EU/GB/US status remains unknown. It is not veterinary-authorised, and all efficacy evidence is indirect or formulation-mismatched, so the PLAYBOOK evidence gate caps scientific credibility at 4.0.
Clinical efficacy 3.5/10
Canine consensus and reviews support antioxidant/anti-inflammatory plausibility but call clinical benefit equivocal. Small studies use different silybin products, complexes or mixed formulations and mostly report biomarkers, not histology, survival or durable disease control. No exact Silarsil outcome trial was found.
Safety and tolerability 5.5/10
The human label and indirect canine studies suggest generally manageable GI and hypersensitivity risk, but exact dog adverse-event frequency, chronic organ-disease exposure, extract variability and interaction magnitude are unknown. Silymarin can inhibit CYP450/P-glycoprotein; polypharmacy requires review.
Clinical practicality 4.0/10
Whole-capsule oral administration is simple only for dogs whose independently justified amount is close to 140 mg. Native-extract dose remains poorly defined, repeated administration may be required, and the capsule cannot be assumed openable or equally divisible.
Full-course cost-effectiveness -
No validated veterinary course duration or current patient-adjusted Georgian course price exists, so cost is excluded.
Important safety and use flags
This is a human medicine. All dog/cat use is off-label, and no exact-product veterinary dose is established. Adjunct only. Diagnose and treat the underlying hepatobiliary disorder; do not substitute Silarsil for nutrition, toxin-specific treatment, antimicrobials, immunosuppression, copper management, biliary intervention or other indicated care. No exact Silarsil dog/cat clinical outcome, PK/bioavailability, target-animal safety or dose-ranging study was located. Biomarker or mechanistic changes do not prove histologic, survival or durable disease benefit. Do not transfer human capsule schedules, intravenous amatoxin/sepsis-study doses, or doses from phosphatidylcholine-complexed silybin and mixed veterinary products. Silymarin effects and exposure are formulation-specific. Give the exact capsule whole unless a product-specific veterinary source validates opening. Powder-content uniformity, equal subdivision, food mixing, palatability and partial-capsule stability are not established. A whole 140 mg capsule is a poor unit for small dogs, and no validated exact-product dog dose identifies which patient can receive one intact capsule. Do not estimate a fraction by eye. Avoid in known milk-thistle/Asteraceae or excipient hypersensitivity. Review lactose, Ponceau 4R and other colourants; stop and reassess for diarrhoea, vomiting, rash, dyspnoea or another new reaction. Review every concurrent medicine and supplement. Silymarin may inhibit CYP450 enzymes and P-glycoprotein; exact clinical interaction magnitude is unknown, especially in polypharmacy. Monitor the disease objectively: clinical status, appetite, weight and condition-specific liver biochemistry, imaging or histology. Stop if no defined benefit appears or the underlying disease progresses. Safety in pregnancy, lactation, breeding animals, neonates and severe renal or multisystem disease is not established for this exact product. Use only after explicit individual benefit-risk review. Assessment sources +
Close
Cat
Possible oral adjunct after veterinarian diagnosis and cause-directed treatment of a hepatobiliary disorder; not acute-toxin rescue, diagnosis or disease-modifying monotherapy
3.2/10
Poor / unconvincing
Details →
vetman assessment
Silarsil
×
140 mg, capsule, human medicine
Assessed clinical scope Cat · Possible oral adjunct after veterinarian diagnosis and cause-directed treatment of a hepatobiliary disorder; not acute-toxin rescue, diagnosis or disease-modifying monotherapy · By mouth
Care setting Veterinarian-directed outpatient adjunct with exact-product and dose-unit review, polypharmacy screening, objective disease monitoring and a defined reassessment/stop point.
vetman score
3.2/10
Poor / unconvincing
Evidence confidence: Low
Georgia: Yes, human · № რ-038256 · Verified on 22 Oct 2026
Off-label use
A poorly matched whole capsule with no exact-product feline efficacy, dose or target-animal safety evidence. Routine feline use is not supported.
Regulatory and scientific credibility 4.0/10
Exact 140 mg/30-capsule identity, World Medicine information and active Georgian and Azerbaijani human registrations are traceable, but EU/GB/US status remains unknown. It is not veterinary-authorised, and all efficacy evidence is indirect or formulation-mismatched, so the PLAYBOOK evidence gate caps scientific credibility at 4.0.
Clinical efficacy 2.5/10
No exact Silarsil or native-silymarin clinical outcome trial in cats was found. The feline evidence base is sparse and dominated by mechanisms, reviews or other products; canine and human findings cannot establish benefit in naturally occurring feline hepatobiliary disease.
Safety and tolerability 4.5/10
Exact feline target-animal safety is absent. Human label tolerance and other-species studies are indirect; the capsule contains lactose, colourants and bovine gelatin, and milk-thistle/Asteraceae hypersensitivity, GI effects and CYP/P-glycoprotein interactions remain relevant uncertainties.
Clinical practicality 1.0/10
One 140 mg whole capsule is grossly mismatched to a typical cat relative to the uncertain native-extract range. The label requires swallowing whole, and opening, equal powder subdivision, food mixing, palatability and partial-capsule stability are unvalidated.
Full-course cost-effectiveness -
No validated veterinary course duration or current patient-adjusted Georgian course price exists, so cost is excluded.
Important safety and use flags
This is a human medicine. All dog/cat use is off-label, and no exact-product veterinary dose is established. Adjunct only. Diagnose and treat the underlying hepatobiliary disorder; do not substitute Silarsil for nutrition, toxin-specific treatment, antimicrobials, immunosuppression, copper management, biliary intervention or other indicated care. No exact Silarsil dog/cat clinical outcome, PK/bioavailability, target-animal safety or dose-ranging study was located. Biomarker or mechanistic changes do not prove histologic, survival or durable disease benefit. Do not transfer human capsule schedules, intravenous amatoxin/sepsis-study doses, or doses from phosphatidylcholine-complexed silybin and mixed veterinary products. Silymarin effects and exposure are formulation-specific. Give the exact capsule whole unless a product-specific veterinary source validates opening. Powder-content uniformity, equal subdivision, food mixing, palatability and partial-capsule stability are not established. A whole 140 mg capsule is grossly mismatched to a typical cat. Do not estimate a fraction by eye or treat the capsule as a calibrated measuring device. Avoid in known milk-thistle/Asteraceae or excipient hypersensitivity. Review lactose, Ponceau 4R and other colourants; stop and reassess for diarrhoea, vomiting, rash, dyspnoea or another new reaction. Review every concurrent medicine and supplement. Silymarin may inhibit CYP450 enzymes and P-glycoprotein; exact clinical interaction magnitude is unknown, especially in polypharmacy. Monitor the disease objectively: clinical status, appetite, weight and condition-specific liver biochemistry, imaging or histology. Stop if no defined benefit appears or the underlying disease progresses. Safety in pregnancy, lactation, breeding animals, neonates and severe renal or multisystem disease is not established for this exact product. Use only after explicit individual benefit-risk review. Assessment sources +
Close
Administration route
By mouth
Registration
Georgia
Yes, human
In force until 01 Jun 2028
Human (Ministry of Health, RAMA)
In the register: Silarsil 140 mg capsules
№ რ-038256
Verified on: 22 Oct 2026
EU
Not confirmed
UK
Not confirmed
US
Not confirmed
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
No exact Silarsil dog or cat dose is established. Native silymarin dose and bioavailability are poorly defined and formulation-specific; do not transfer the human schedule, intravenous toxin-study doses or enhanced-bioavailability veterinary-product doses. The exact capsule is swallowed whole and is not a validated divisible dose unit.
